Nuclear Dot Pattern on ANA Test: What Few and Multiple Nuclear Dots Mean

Sample type: Serum

Other names: Nuclear Dot Pattern, Nuclear Dot Pattern ANA, ANA Nuclear Dot Pattern, Nuclear Dots ANA, ANA Nuclear Dots, Nuclear Dots ANA Pattern, Nuclear Dot Pattern High, Discrete Nuclear Dots, Discrete Nuclear Dots ANA, ANA Discrete Nuclear Dots, Discrete Nuclear Dots ANA Pattern, Few Nuclear Dots ANA, ANA Few Nuclear Dots, Few Nuclear Dots ANA Pattern, ANA Pattern Few Nuclear Dots, Multiple Nuclear Dots ANA, ANA Multiple Nuclear Dots, Multiple Nuclear Dots ANA Pattern, ANA Pattern Multiple Nuclear Dots, Nuclear Dot Pattern Positive, Positive ANA Nuclear Dots Pattern, ANA Pattern Nuclear Dots, Nuclear Dots, Nuclear Dot, ANA Nuclear Dots Pattern, Nuclear Dot ANA, AC-6 Multiple Nuclear Dots, AC-6 ANA Pattern, AC-7 Few Nuclear Dots, AC-7 ANA Pattern, ICAP AC-6, ICAP AC-7, Nuclear Dot Pattern 1:80, Nuclear Dot Pattern 1:160, Nuclear Dot Pattern 1:320, Nuclear Dot Pattern 1:640, Nuclear Dot 1:320, ANA Nuclear Dot Pattern 1:160, What Does Discrete Nuclear Dots Mean, What is Nuclear Dot Pattern, Nuclear Dot Primary Biliary Cholangitis, Nuclear Dot Pattern PBC, SP100 Antibody ANA, Anti-Sp100, Anti-Sp140, Anti-PML Antibody, Anti-NXP-2 Antibody, Anti-MJ Antibody, PML Protein, SP100, Nuclear Dots Bedeutung (German), Nuclear Dots Pattern Bedeutung (German), ANA Patron Nuclear Dots (Spanish), Anticuerpos Antinucleares Nuclear Dots (Spanish), Nucleaire Patroon Nuclear Dots (Dutch), ANA Pattern Nuclear Dots Meaning, Nuclear Dot Pattern Significance, Nuclear Multiple Nuclear Dots, Nuclear Discrete Nuclear Dots, Cajal Body Pattern ANA, Coilin Antibody ANA, p80-coilin Antibody, SMN Complex Antibody, Nuclear Dot Pattern Autoimmune, ANA Nuclear Dot Pattern Significance, Nuclear Dot Pattern Diseases, What Does Nuclear Dot Pattern Mean, ANA Pattern Nuclear Dot Meaning, Positive ANA Nuclear Dot Pattern High, AMA Negative PBC ANA Pattern, Anti-GP210, Nuclear Envelope ANA Pattern PBC

Low

The nuclear dot pattern is only reported when the antinuclear antibody (ANA) test by indirect fluorescent antibody (IFA) method returns a positive result. When the ANA is negative, no fluorescence pattern — including nuclear dot pattern — is reported, because there are no antinuclear antibodies present above the detection threshold to produce a pattern.

A negative ANA result (and therefore the absence of any nuclear dot pattern) means no antinuclear antibodies were detected above the reporting threshold at the time of testing. This is the expected, normal result for most individuals and is highly reassuring in the context of suspected autoimmune liver disease or connective tissue disease. A negative ANA does not completely exclude primary biliary cholangitis in all cases — a small proportion of PBC patients are ANA-negative — but in combination with a negative anti-mitochondrial antibody (AMA) and normal alkaline phosphatase and GGT, a negative ANA makes PBC unlikely.

If you are viewing this page because your HealthMatters dashboard shows no nuclear dot pattern result, or shows the ANA as Negative, this is the expected normal finding. No follow-up testing is required for the nuclear dot pattern specifically in the absence of a positive ANA or symptoms suggestive of autoimmune liver or connective tissue disease.

High

A positive nuclear dot pattern on the antinuclear antibody (ANA) by IFA test indicates that antinuclear antibodies are present that target specific nuclear body proteins. The clinical significance depends critically on which sub-type is identified. The multiple nuclear dots pattern (AC-6), classically around 6–20 dots per nucleus, is most commonly linked to primary biliary cholangitis (PBC) through anti-Sp100 and anti-Sp140 antibodies that target PML nuclear bodies; it can also occur in dermatomyositis context when anti-NXP-2/MJ is the responsible antibody. The few nuclear dots pattern (AC-7), classically 1–6 dots per nucleus, has low positive predictive value for any specific disease and is often incidental. A positive AC-6 pattern is a meaningful pointer toward PBC evaluation, particularly when alkaline phosphatase or GGT is elevated, AMA is positive or unavailable, or symptoms such as fatigue and itching are present — but the pattern alone does not diagnose PBC. When AC-6 is identified alongside cholestatic liver enzymes and PBC-specific antibodies (anti-Sp100, AMA, or anti-gp210), hepatology evaluation is appropriate. If PBC is diagnosed, first-line treatment with ursodeoxycholic acid (UDCA) is effective and response is monitored with liver enzymes over time.

QUICK ANSWER

The nuclear dot pattern is a specific fluorescence pattern seen on a positive ANA by IFA test. Discrete bright dots appear within cell nuclei under the microscope. There are two main types — and distinguishing between them matters clinically.

Sub-type ICAP code Dots per nucleus Primary association
Multiple nuclear dots AC-6 Classically ~6–20 per cell Primary biliary cholangitis (PBC); anti-Sp100 and anti-Sp140 antibodies
Few nuclear dots AC-7 Classically ~1–6 per cell Low positive predictive value; p80-coilin / SMN complex; often incidental

Common questions at a glance:

Question Short answer
What does nuclear dot pattern mean on ANA? Discrete bright dots within cell nuclei — a specific ANA fluorescence pattern
What does "multiple nuclear dots" mean? ~6–20 dots per nucleus (AC-6); most commonly associated with primary biliary cholangitis
What does "few nuclear dots" mean? ~1–6 dots per nucleus (AC-7); low positive predictive value; often incidental
What does "discrete nuclear dots" mean? Same as nuclear dot pattern — "discrete" describes the sharply defined appearance of the dots
What does "nuclear dot pattern high" mean? A positive nuclear dot pattern with a high titer — the number refers to antibody concentration, not dot count
What diseases are associated with nuclear dot pattern? AC-6: primarily PBC; AC-7: low disease specificity

WHAT IS THE NUCLEAR DOT PATTERN?

The nuclear dot pattern is one of the recognized ANA fluorescence patterns classified by the International Consensus on ANA Patterns (ICAP). When a blood sample is tested for antinuclear antibodies by indirect fluorescent antibody (IFA) method, the serum is applied to HEp-2 cells on a glass slide. If antinuclear antibodies are present, they bind to specific structures inside the cell nucleus, producing a fluorescence pattern visible under a fluorescent microscope.

The nuclear dot pattern appears as a small number of sharply defined (discrete) bright fluorescent dots located within the nucleus — distinct from the diffuse or granular staining of other ANA patterns. The dots correspond to specific nuclear bodies — compact protein structures inside the nucleus that serve regulatory functions in gene expression, antiviral response, and protein processing.

Why the nuclear dot pattern is distinct from other ANA patterns:

Pattern Appearance under microscope Key distinction from nuclear dots
Nuclear dot (AC-6/AC-7) Small number of discrete bright dots within the nucleus Dots are few and sharply defined
Homogeneous Uniform staining across the entire nucleus Diffuse — no distinct dots
Speckled Fine or coarse granular staining throughout nucleus More numerous and less distinct than nuclear dots
Nucleolar Staining concentrated in the nucleolus Located in nucleolus, not in nuclear body dots
Centromere (AC-3) Many dots at centromere/kinetochore positions — ICAP describes ~40–80 per cell Many more dots than nuclear dot pattern

FEW NUCLEAR DOTS VS MULTIPLE NUCLEAR DOTS — THE KEY DISTINCTION

The ICAP nomenclature divides the nuclear dot pattern into two distinct sub-types. The distinction has significant clinical relevance.

AC-6: Multiple Nuclear Dots

Feature Details
Appearance Classically ~6–20 discrete dots per cell (ICAP); the lab's pattern call matters more than counting yourself
ICAP code AC-6
Nuclear structure targeted PML nuclear bodies (also called ND10 bodies) — protein complexes involved in antiviral response, DNA repair, and gene regulation
Associated antibodies Anti-Sp100 (most common, PBC context), anti-Sp140 (PBC context), anti-NXP-2/MJ (dermatomyositis context)
Primary clinical association Primary biliary cholangitis (PBC) — the strongest and most consistent disease association for anti-Sp100/Sp140
Other associations Autoimmune hepatitis, PBC/AIH overlap syndrome, dermatomyositis (when anti-NXP-2 is the responsible antibody)
Clinical significance More diagnostically meaningful than AC-7; anti-Sp100 and anti-Sp140 are clinically validated PBC markers

AC-7: Few Nuclear Dots

Feature Details
Appearance Classically ~1–6 discrete dots per cell (ICAP)
ICAP code AC-7
Associated antigens p80-coilin and SMN complex proteins
Nuclear structure targeted Cajal bodies (coiled bodies) and nuclear gems — structures involved in RNA processing
Disease association Low positive predictive value for any specific disease (ICAP)
Testing limitation Specific commercial immunoassays for p80-coilin/SMN complex antibodies are not routinely available
Clinical significance Usually interpreted with symptoms, titer, and other findings; substantially less specific than AC-6

Important: The split between AC-6 and AC-7 is based on the laboratory's pattern call and any ICAP code provided — not on counting dots yourself. Because the ranges overlap at approximately 6 dots per cell, the lab's reported sub-type or ICAP code is the authoritative classification.


WHAT DOES "DISCRETE NUCLEAR DOTS" MEAN?

"Discrete nuclear dots" is the descriptive term laboratories use to report the nuclear dot ANA pattern. "Discrete" refers to the sharply defined, individually distinct appearance of the dots — each dot is separate and clearly bounded, unlike the more diffuse or granular staining of other ANA patterns.

When your report says "Discrete Nuclear Dots," it is describing the same finding as "nuclear dot pattern." The word "discrete" is a morphological descriptor telling you the dots are well-defined and individually distinguishable — it does not mean the finding is separate from your ANA result or indicate a specific severity level.


WHAT DOES "NUCLEAR DOT PATTERN HIGH" MEAN?

When a report states "nuclear dot pattern high" or shows the pattern alongside a high titer, the "high" refers to the ANA titer — the dilution at which antibodies remain detectable — not to the number of dots or the pattern's appearance.

Titer with nuclear dot pattern Clinical interpretation
1:40 Low positive — may be incidental; clinical correlation required
1:80 Low positive — requires clinical context; common even in healthy individuals
1:160 More likely to be clinically meaningful than very low titers; consider sub-type, symptoms, liver enzymes, and specific antibody testing
1:320 Higher positive — more concerning when AC-6 is present with cholestatic liver enzymes or PBC-specific antibodies
1:640 and above High titer — more clinically significant, especially with AC-6 and cholestatic pattern; titer alone does not diagnose disease

For nuclear dot pattern, the most important interpretation variables are: AC-6 vs AC-7, titer, ALP/GGT pattern, AMA status, anti-Sp100/Sp140/gp210 results, and symptoms.


PRIMARY CLINICAL ASSOCIATION — PRIMARY BILIARY CHOLANGITIS (PBC)

The multiple nuclear dots pattern (AC-6) is one of the ANA patterns most specifically associated with primary biliary cholangitis (PBC) — a chronic autoimmune liver disease affecting the small bile ducts. A positive AC-6 pattern is a meaningful clue that should prompt PBC evaluation, especially when alkaline phosphatase or GGT is elevated, AMA is positive or unavailable, or symptoms such as itching and fatigue are present. The pattern alone does not diagnose PBC.

What is PBC? Primary biliary cholangitis (formerly called primary biliary cirrhosis) is an autoimmune condition in which the immune system attacks the small bile ducts inside the liver, causing progressive inflammation and scarring. It predominantly affects middle-aged women. Common symptoms include fatigue and itching (pruritus). Elevated alkaline phosphatase (ALP) and GGT are the characteristic biochemical findings. If diagnosed, first-line treatment is ursodeoxycholic acid (UDCA), and response is monitored with liver enzymes over time. Treatment is considered only if PBC is clinically diagnosed — a nuclear dot pattern alone is not a reason to start UDCA.

ANA patterns in PBC:

ANA pattern Antibody Prevalence in PBC Clinical significance
Multiple nuclear dots (AC-6) Anti-Sp100, anti-Sp140 ~25–30% of PBC patients Highly specific for PBC; particularly useful when AMA is negative
Nuclear envelope/rim Anti-gp210, anti-p62 ~20–25% of PBC patients Also PBC-associated; anti-gp210 may indicate more progressive disease
Speckled Various Common but less specific Less diagnostically specific for PBC

PBC evaluation components when nuclear dots are found:

Component Why it matters
Alkaline phosphatase (ALP) Key cholestatic liver enzyme; persistent elevation is central to PBC evaluation
GGT Supports cholestatic liver pattern when ALP is elevated
AMA / AMA-M2 Primary PBC antibody; positive in most PBC cases
Anti-Sp100 / anti-Sp140 PBC-specific nuclear body antibodies; especially useful when AMA is negative
Anti-gp210 PBC-specific nuclear envelope antibody; may suggest more aggressive disease course
Bilirubin, albumin, platelets, INR Help assess liver function and disease severity
Liver ultrasound Helps exclude biliary obstruction or other structural liver disease
Hepatology referral Appropriate when nuclear dots occur with cholestatic liver enzymes or PBC-specific antibodies

Anti-Sp100: Anti-Sp100 targets the Sp100 nuclear antigen — a component of PML nuclear bodies. It is highly specific for PBC and is the antibody most commonly responsible for the AC-6 pattern in a liver disease context. Anti-Sp140, sometimes discussed in the broader PML nuclear body antibody context, may be included in some liver autoantibody profiles; in routine PBC evaluation, anti-Sp100 and anti-gp210 are more commonly emphasized clinically, especially when AMA is negative.


WHY NUCLEAR DOTS MATTER WHEN AMA IS NEGATIVE

Most PBC patients test positive for anti-mitochondrial antibody (AMA) — the primary PBC serological marker. However, a minority of PBC patients are AMA-negative. In that situation, PBC-specific ANA patterns and antibodies become especially important for diagnosis.

According to AASLD and EASL PBC guidelines, PBC can be established in AMA-negative patients when cholestatic liver enzyme elevation is present alongside PBC-specific ANA immunofluorescence patterns — such as the multiple nuclear dots pattern — or PBC-specific antibodies including anti-Sp100 and anti-gp210.

This is why a multiple nuclear dots (AC-6) finding should always be interpreted alongside ALP, GGT, AMA, anti-Sp100, anti-Sp140, anti-gp210, and symptoms such as itching or fatigue — particularly when AMA is unavailable or negative.

What if AMA or anti-Sp100 is positive but ALP and GGT are completely normal? A positive PBC-associated antibody without cholestatic liver enzyme elevation does not automatically diagnose PBC. In this situation, clinicians usually monitor liver enzymes over time and interpret the result with symptoms, imaging, and antibody profile. Current guidelines note that AMA alone without cholestatic biochemistry is not sufficient to diagnose PBC.


NUCLEAR DOT PATTERN VS NUCLEAR ENVELOPE/RIM PATTERN — A COMMON PBC CONFUSION

Both multiple nuclear dots and nuclear envelope/rim are PBC-associated ANA patterns, but they are different findings produced by different antibodies:

Pattern ICAP code Appearance PBC antibody context
Multiple nuclear dots AC-6 Multiple discrete dots within the nucleus Anti-Sp100, anti-Sp140 — PBC-associated
Nuclear envelope/rim AC-11 and related Staining around the border of the nucleus Anti-gp210, anti-p62 — PBC-associated; anti-gp210 may indicate more aggressive disease course
Centromere AC-3 Many dots (~40–80 per cell) at kinetochore positions Anti-centromere — limited systemic sclerosis/CREST, not PBC

Both nuclear dots (AC-6) and nuclear envelope/rim can be seen in PBC patients, and some patients may have both patterns. Neither individually diagnoses PBC — both require clinical and biochemical correlation.


WHAT DOES NUCLEAR DOT PATTERN MEAN FOR OTHER CONDITIONS?

While PBC is the primary association for AC-6, nuclear dot patterns can also be seen in:

Condition Notes
Autoimmune hepatitis (AIH) Nuclear dot pattern may appear in AIH/PBC overlap syndrome
PBC/AIH overlap syndrome One of the most clinically important contexts — both patterns and specific antibodies guide management
Dermatomyositis / inflammatory myopathy When anti-NXP-2/MJ is the responsible antibody rather than anti-Sp100/Sp140 — different clinical context entirely
Sjögren's syndrome Occasional association; usually accompanied by anti-SSA/Ro antibodies
Healthy individuals AC-7 (few nuclear dots) may be seen as an incidental finding, particularly at low titer; ICAP notes AC-7 has low positive predictive value

Anti-NXP-2/MJ and dermatomyositis: Anti-NXP-2/MJ is a myositis-associated antibody that can produce a multiple nuclear dots pattern on HEp-2 cells. It is most relevant when the patient has dermatomyositis or inflammatory myopathy features such as proximal muscle weakness, elevated CK or aldolase, characteristic rash (heliotrope rash, Gottron's papules), or dysphagia. In adults with confirmed inflammatory myopathy, anti-NXP-2 has been reported in association with malignancy risk, but a nuclear dot pattern alone does not indicate cancer — clinical context and specific antibody testing determine whether NXP-2 follow-up is appropriate.


SELECTED ICAP NUCLEAR PATTERN CODES RELEVANT TO NUCLEAR DOTS

Some laboratory reports use ICAP (International Consensus on ANA Patterns) AC-code nomenclature. Here are the codes most relevant when interpreting nuclear dot results:

ICAP code Pattern name Description
AC-1 Homogeneous Uniform nuclear staining
AC-2, AC-3, AC-4, AC-5 Speckled variants Fine or coarse granular nuclear staining
AC-6 Multiple nuclear dots ~6–20 discrete nuclear dots per cell; PML nuclear bodies
AC-7 Few nuclear dots ~1–6 discrete nuclear dots per cell; Cajal bodies
AC-8, AC-9, AC-10 Nucleolar patterns Staining in nucleolus
AC-11 Nuclear envelope/rim Staining at nuclear border; PBC-associated
AC-3 Centromere ~40–80 dots at kinetochore positions; limited systemic sclerosis
AC-13 PCNA Proliferating cell nuclear antigen pattern
AC-29 Dense fine speckled (DFS70) DFS70/LEDGFp75 antibody

Note: ICAP also lists additional pattern codes (AC-30, AC-31, and others) for less common patterns. If you see an AC code not listed here, refer to the ICAP website (anapatterns.org) for the full current classification.


SPECIFIC ANTIBODY FOLLOW-UP AFTER NUCLEAR DOT PATTERN

A positive nuclear dot pattern on ANA by IFA typically prompts follow-up with specific antibody tests:

Follow-up test Why ordered after nuclear dot pattern
Anti-Sp100 Most common AC-6 antibody in PBC context; highly specific for PBC
Anti-Sp140 Related PBC-associated PML nuclear body antigen; included in some liver autoantibody profiles
AMA / AMA-M2 Primary PBC antibody; ordered to complete PBC workup
Anti-gp210 PBC-specific nuclear envelope antibody; not a nuclear dot antibody, but ordered in PBC workup
ALP, GGT, bilirubin, ALT/AST Biochemical liver context to determine if cholestatic pattern is present
Anti-NXP-2/MJ Consider only if dermatomyositis or inflammatory myopathy features are present (muscle weakness, elevated CK)
Anti-coilin / SMN complex AC-7/few nuclear dots context; specific commercial tests not routinely available

WHEN SHOULD I WORRY ABOUT A NUCLEAR DOT PATTERN?

Situation Concern level Suggested follow-up
AC-7 few nuclear dots + low titer + no symptoms Low Clinical correlation; usually not urgent; ICAP notes low positive predictive value
AC-6 multiple nuclear dots + normal ALP/GGT + no symptoms Low-Moderate Check AMA/AMA-M2, anti-Sp100/Sp140/gp210; monitor liver enzymes over time
AC-6 + elevated ALP or GGT Moderate-High PBC workup; hepatology referral
AC-6 + positive AMA or anti-Sp100 Moderate-High PBC evaluation; hepatology referral
AC-6 + elevated ALP/GGT + AMA negative Moderate-High Anti-Sp100, anti-Sp140, anti-gp210 testing; hepatology referral — this is a key scenario for AMA-negative PBC
Nuclear dots + muscle weakness + elevated CK/aldolase Moderate-High Myositis evaluation; anti-NXP-2/MJ testing; rheumatology referral
Nuclear dots + jaundice, severe itching, dark urine, pale stools Higher urgency Prompt medical evaluation

MOST COMMON CLINICAL SCENARIOS

Pattern Most likely interpretation Recommended next step
AC-6 + fatigue + elevated ALP Probable PBC — classic presentation Anti-Sp100, AMA, GGT, bilirubin; hepatology referral
AC-6 + normal ALP/GGT + no symptoms Possible early/incidental finding; PBC not diagnosed from pattern alone Check AMA/AMA-M2 and anti-Sp100/Sp140/gp210; repeat liver enzymes with clinician guidance
AC-6 + elevated ALP/GGT + positive anti-Sp100 or AMA Strong PBC evaluation pattern Hepatology referral
AC-6 + elevated ALP/GGT + AMA negative + anti-Sp100 positive AMA-negative PBC pattern Hepatology referral; UDCA evaluation
AC-7 + no symptoms + low titer Likely incidental; low clinical significance Clinical correlation; avoid overdiagnosis; no urgent action needed
AC-7 + autoimmune symptoms Requires clinical context Specific antibody testing; evaluate with other clinical findings
Nuclear dot pattern + high titer (1:320+) + liver symptoms Clinically significant Full PBC workup; hepatology evaluation
Nuclear dot pattern (AC-6) + positive anti-NXP-2 + muscle weakness Dermatomyositis context Myositis evaluation; muscle enzymes; rheumatology referral
Nuclear dot pattern + ANA 12 Plus Profile ordered ANA 12 Plus Profile includes broad autoimmune markers but does not include PBC-specific anti-Sp100, anti-Sp140, anti-gp210, or AMA If AC-6 is reported, order liver-focused follow-up separately: ALP, GGT, AMA/AMA-M2, anti-Sp100/Sp140, anti-gp210; hepatology evaluation if liver markers are abnormal
Nuclear Dot Pattern
Healthmatters dashboard showing biomarker trend graph

Every lab result you’ve ever had, charted and explained.

Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.

Start with my report →
Beyond Nuclear Dot Pattern — 10,000+ markers explained
One Nuclear Dot Pattern result tells you where you are. Your history tells you where you’re heading. Upload your past lab reports and see this marker — and every marker on them —every marker charted against your own lab’s ranges.
Start with this report →
Healthmatters timeline preview showing biomarker trends over time

Frequently Asked Questions

What does nuclear dot pattern mean on an ANA test?
The nuclear dot pattern is a fluorescence pattern seen when a positive ANA by IFA test is examined under a fluorescent microscope. Instead of diffuse or granular staining, the nuclear dot pattern appears as a small number of sharply defined bright spots within the nucleus. These dots correspond to specific protein structures called nuclear bodies — particularly PML nuclear bodies (AC-6) or Cajal bodies (AC-7). The ICAP nomenclature divides the pattern into multiple nuclear dots (AC-6, classically ~6–20 dots per cell, most associated with primary biliary cholangitis through anti-Sp100 and anti-Sp140) and few nuclear dots (AC-7, classically ~1–6 dots per cell, with low positive predictive value for any specific disease).
What does "discrete nuclear dots" mean?
"Discrete nuclear dots" is the descriptive term laboratories use to report the nuclear dot ANA pattern. "Discrete" refers to the morphological appearance — the dots are sharply defined and individually distinguishable under the microscope. When your report says "Discrete Nuclear Dots," it is describing the same finding as "nuclear dot pattern." The word "discrete" is not a clinical category or severity indicator. The clinically important question is whether the report specifies few or multiple nuclear dots — which determines the likely associated antibody and disease association.
What does "few nuclear dots" mean on an ANA test?
Few nuclear dots refers to the AC-7 sub-type, where classically approximately 1–6 discrete dots are visible per nucleus under fluorescent microscopy. AC-7 is associated with antibodies to p80-coilin and SMN complex proteins that target Cajal bodies inside the nucleus. Importantly, ICAP notes that AC-7 has low positive predictive value for any specific disease. Specific commercial tests for p80-coilin/SMN antibodies are not routinely available. AC-7 at low titer with no symptoms is often an incidental finding that does not indicate a specific autoimmune disease.
What does "multiple nuclear dots" mean on an ANA test?
Multiple nuclear dots refers to the AC-6 sub-type, where classically approximately 6–20 discrete dots are visible per nucleus under fluorescent microscopy. This pattern is produced by antibodies targeting PML nuclear bodies — most commonly anti-Sp100 and anti-Sp140 in the context of primary biliary cholangitis (PBC), or anti-NXP-2/MJ in the context of dermatomyositis or inflammatory myopathy. AC-6 is considered more clinically specific than AC-7. When this pattern is identified, follow-up testing with anti-Sp100, anti-Sp140, AMA, and liver enzyme evaluation is typically recommended.
What diseases are associated with the nuclear dot ANA pattern?
The multiple nuclear dots pattern (AC-6) is most strongly associated with primary biliary cholangitis (PBC) — anti-Sp100 and anti-Sp140 are found in approximately 25–30% of PBC patients and are considered highly specific PBC markers, particularly useful when the primary PBC antibody (AMA) is negative. AC-6 can also be seen in autoimmune hepatitis and PBC/AIH overlap syndromes. When anti-NXP-2/MJ is the responsible antibody rather than anti-Sp100, the AC-6 pattern occurs in dermatomyositis context. The few nuclear dots pattern (AC-7) has low positive predictive value for any specific disease.
What does "nuclear dot pattern high" mean?
"Nuclear dot pattern high" means a positive nuclear dot ANA pattern with a high titer — the "high" refers to the antibody concentration, not the number of dots. High titer means antibodies remain detectable at a high dilution of the blood sample (such as 1:320 or 1:640). A high-titer AC-6 nuclear dot pattern in a patient with elevated ALP/GGT and positive anti-Sp100 would be a clinically significant constellation pointing toward PBC evaluation. Titer alone does not diagnose disease — the sub-type, liver enzymes, and specific antibody results all matter.
Is a nuclear dot pattern on ANA serious?
It depends on which sub-type is identified. AC-6 (multiple nuclear dots) at a significant titer warrants evaluation for primary biliary cholangitis, particularly with symptoms such as fatigue, itching, or elevated liver enzymes. PBC is very manageable when identified early — first-line treatment with ursodeoxycholic acid (UDCA) is effective and well-tolerated. AC-7 (few nuclear dots) with no symptoms and low titer is often an incidental finding with low positive predictive value. A nuclear dot pattern is not a medical emergency — it is a finding that guides what specific tests to do next.
What is anti-Sp100 and why is it important?
Anti-Sp100 targets the Sp100 nuclear antigen, a protein found in PML nuclear bodies inside the nucleus. It is one of the main antibodies responsible for the AC-6 (multiple nuclear dots) pattern. Anti-Sp100 is considered highly specific for primary biliary cholangitis (PBC) and is clinically useful particularly in patients who are AMA-negative but have clinical and biochemical features suggesting PBC. Anti-Sp140, sometimes discussed in the broader PML nuclear body antibody context, may be included in some liver autoantibody profiles; in routine PBC evaluation, anti-Sp100 and anti-gp210 are the more commonly emphasized markers, especially when AMA is negative. A positive anti-Sp100 in the right clinical and biochemical context supports PBC evaluation.
What is the difference between nuclear dot pattern and centromere pattern on ANA?
Both produce discrete dots on ANA by IFA, which can cause confusion. The key differences are: centromere pattern (AC-3) shows many more dots — ICAP describes approximately 40–80 per cell — corresponding to kinetochore/centromere staining at each chromosome, is associated with anti-centromere antibodies, and is linked to limited systemic sclerosis (CREST syndrome). Nuclear dot pattern (AC-6/AC-7) shows far fewer dots per nucleus and is associated with different antibodies (anti-Sp100, anti-Sp140) and different diseases (primarily PBC). The number of dots per nucleus and the clinical context are the key distinguishing factors.
Can a nuclear dot pattern be seen in healthy people?
Yes — particularly the few nuclear dots pattern (AC-7) at low titer. ICAP notes that AC-7 has low positive predictive value for any specific disease, and it can be found as an incidental finding in people without autoimmune disease. The multiple nuclear dots pattern (AC-6) is more clinically meaningful, especially when paired with PBC-specific antibodies or cholestatic liver enzymes, but even AC-6 should not be interpreted without the full clinical picture including symptoms, liver enzymes, and specific antibody results.
Does a nuclear dot pattern mean I have PBC?
No — a nuclear dot pattern does not diagnose PBC by itself. Multiple nuclear dots (AC-6) is a recognized PBC-associated pattern, and when anti-Sp100 or related PBC-specific antibodies are also positive, it is a meaningful pointer toward PBC evaluation. However, PBC diagnosis requires the combination of cholestatic liver enzyme elevation, PBC-specific antibodies (AMA, anti-Sp100, or anti-gp210), and sometimes liver histology. The pattern alone — without biochemical or serological support — is not sufficient to establish a PBC diagnosis.
Clinical Sources & References

All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.

  1. International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results
    Auto Immun Highlights. · 2016 View source ↗
  2. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases
    Hepatology. · 2019 View source ↗
  3. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis
    J Hepatol. · 2017 View source ↗
  4. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies
    Ann Rheum Dis. · 2014 View source ↗
  5. Autoimmune liver serology: current diagnostic and clinical challenges
    World J Gastroenterol. · 2008 View source ↗
  6. AC-6 Multiple Nuclear Dots.
    ICAP — International Consensus on ANA Patterns. · 2025 View source ↗
  7. AC-7 Few Nuclear Dots.
    ICAP — International Consensus on ANA Patterns. · 2025 View source ↗
  8. PBC2
    Mayo Clinic Laboratories. · 2025 View source ↗
Article Review Log
Last reviewed June 21, 2026
Originally published June 21, 2026
Reviewed by HealthMatters Editorial Team
Written by Healthmatters Editorial Team
Healthmatters Lifetime Plan

Pay $250. Track your health forever

One payment. No renewals. Yours for life.

10,000+ biomarkers explained · trends over time

See other plans →
Secure checkout via Stripe · GDPR & HIPAA
We accept results from any lab
LabCorp Quest Diagnostics Genova Diagnostics DUTCH Test Doctor's Data Vibrant America ZRT Laboratory Cyrex Labs + any other lab

What members are saying

★★★★★ 10,000+ happy members
★★★★★

"Watching my numbers move over the years — instead of forgetting last time's results — completely changed how I manage my health."

Daniel
Member since 2022
★★★★★

"Living across several countries made keeping my lab results organized a real challenge. Healthmatters brought my results from the USA, Spain, and Germany together — 20 years of history, with long-term trends instead of scattered reports."

Ben
Member since 2021 · tracks across countries
★★★★★

"Standard lab ranges are too wide for how I practice — 'normal' isn't optimal. I set my own bands, so a client sees yellow before a marker goes officially out of range. That's the conversation I want to be having."

Dr. Alexandra
Functional medicine · 6 yrs on Pro